Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
← catalyst calendarNCT02428218 · readout ≤ 165 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 3
Status
Withdrawn
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Feasibility
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | May 2016 | not stated | When the study began enrolling |
| Primary completion | Jan 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2015-04-28 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2016-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Relapsing-Remitting Multiple Sclerosis
- Relapsing Forms of Multiple Sclerosis
Interventions
- Drug: dimethyl fumarate — also filed as BG00012, DMF
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to first multiple sclerosis (MS) relapse
measured Up to week 104
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed